An Interventional Efficacy and Safety, Phase 2, Randomized, Double-Blind, 3‑Arm Study to Investigate Nirmatrelvir/Ritonavir in Nonhospitalized Participants at Least 12 Years of Age With Symptomatic COVID‑19 Who Are Immunocompromised

A Study to Learn About the Study Medicines (Nirmatrelvir plus Ritonavir) in People aged 12 Years or Older With COVID-19 and a compromised immune system

Category & Conditions: Infections and Infectious Diseases

Medicine: PAXLOVID

ClinicalTrials.gov Identifier (NCT): An Interventional Efficacy and Safety, Phase 2, Randomized, Double-Blind, 3‑Arm…

Protocol ID: C4671034

Print Download

Open Plain Language Summary Result: Click here